var data={"title":"Omega-3-acid ethyl esters (fish oil): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Omega-3-acid ethyl esters (fish oil): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6199?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=omega-3-acid-ethyl-esters-fish-oil-patient-drug-information\" class=\"drug drug_patient\">see &quot;Omega-3-acid ethyl esters (fish oil): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171381\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Dialyvite Omega-3 Concentrate [OTC];</li>\n      <li>Expecta LIPIL [OTC] [DSC];</li>\n      <li>Fish Oil Ultra [OTC] [DSC];</li>\n      <li>Lovaza;</li>\n      <li>Maximum Red Krill [OTC];</li>\n      <li>Ocean Blue MiniCaps Omega-3 [OTC];</li>\n      <li>Omega Power [OTC];</li>\n      <li>Omega-3 2100 [OTC];</li>\n      <li>Omega-3 Fish Oil Ex St [OTC];</li>\n      <li>Omega-3 IQ [OTC];</li>\n      <li>Pro Nutrients Omega 3 [OTC];</li>\n      <li>Salmon Oil-1000 [OTC];</li>\n      <li>Sam-E.P.A. [OTC];</li>\n      <li>Sea-Omega [OTC];</li>\n      <li>Triklo;</li>\n      <li>Vascepa</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171400\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antilipemic Agent, Omega-3 Fatty Acids</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171384\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypertriglyceridemia:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Epanova: 2 g (2 capsules) or 4 g (4 capsules) once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Lovaza: 4 g (4 capsules) once daily or 2 g (2 capsules) twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Vascepa: 2 g (2 [1 gram] capsules or 4 [0.5 g] capsules) twice daily with meals</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>IgA nephropathy (off-label use):</b> Oral: Lovaza: 4 g (4 capsules) once daily (Donadio 2001)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171385\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171386\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied). EPA and DHA are not renally eliminated.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15795613\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171368\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dialyvite Omega-3 Concentrate: 600 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Expecta LIPIL: 200 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Fish Oil Ultra: 1000 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lovaza: 1 g [contains soybean oil, tocopherol, dl-alpha]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ocean Blue MiniCaps Omega-3: 350 mg [gluten free, lactose free, sugar free; contains fd&amp;c red #40, fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Omega Power: 1050 mg [gluten free, lactose free, sugar free; contains fd&amp;c red #40, fd&amp;c yellow #10 (quinoline yellow); vanilla flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Omega-3 2100: 1050 mg [odorless; orange flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Triklo: 1 g</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vascepa: 0.5 g, 1 g</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 300 mg, 500 mg, 1000 mg, 1 g</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Maximum Red Krill: 300 mg [gluten free; contains soybean oil]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Omega-3 Fish Oil Ex St: 880 mg [gluten free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Salmon Oil-1000: 200 mg [corn free, rye free, starch free, sugar free, wheat free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sam-E.P.A.: 200-300 MG [dye free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sea-Omega: 1000 mg [cholesterol free, corn free, gluten free, milk derivatives/products, no artificial color(s), no artificial flavor(s), sodium free, starch free, sugar free, yeast free; contains soybeans (glycine max)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 200 mg, 1000 mg, 1200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule Delayed Release, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pro Nutrients Omega 3: 332.5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1000 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Chewable, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Omega-3 IQ: 240 mg [fruit flavor]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24526958\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25177479\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Epanova: Each 1 g capsule contains at least 850 mg of polyunsaturated fatty acids, including multiple omega-3 fatty acids (eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA] being the most abundant).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lovaza: Each 1 g capsule contains the combination of EPA (~465 mg) and DHA (~375 mg) ethyl esters.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vascepa: Icosapent ethyl contains ethyl esters of an omega-3 fatty acid, EPA, obtained from fish oil. It contains &ge;96% EPA and does <b>not</b> contain DHA. Historically, mixtures containing both EPA and DHA have increased LDL cholesterol in patients with severe hypertriglyceridemia. However, studies have suggested that icosapent ethyl has not caused significant increases in LDL cholesterol while significantly decreasing triglyceride levels (Bays 2011; Miller 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24757877\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Epanova: FDA approved May 2014; anticipated availability is currently unknown.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171371\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Epanova, Lovaza: Administer with or without food. Administer whole; do not break, crush, dissolve, or chew.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vascepa: Administer with meals. Administer whole; do not break, crush, dissolve, or chew.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171370\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dietary supplement:</b> As dietary supplements for patients at early risk of coronary artery disease primarily because of effects on platelets and lipids.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Prior recommendations from the American Heart Association (AHA) stated that patients without documented coronary heart disease (CHD) should eat a variety of fish, preferably oily fish (eg, salmon), at least twice a week, or daily (as oily fish, but omega-3 fatty acids may be considered) in patients with documented CHD (AHA [Kris-Etherton 2002]). According to the most recent AHA recommendations, the use of omega-3 fatty acids is reasonable only for the secondary prevention of CHD and sudden cardiac death among patients with prevalent CHD and secondary prevention of outcomes in patients with heart failure (AHA [Siscovick 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypertriglyceridemia (Lovaza, Epanova, and Vascepa):</b> As an adjunct to diet to reduce triglyceride levels in adults with severe (&ge;500 mg/dL) hypertriglyceridemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> The Endocrine Society recommends that omega-3 fatty acids may be considered for triglyceride levels &gt;1,000 mg/dL and may be used alone or in combination with HMG-CoA reductase inhibitors (Berglund 2012). A number of OTC formulations containing omega-3 fatty acids are marketed as nutritional supplements; these do not have FDA-approved indications and may not contain the same amounts of the active ingredient.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25469482\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>IgA nephropathy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1959598\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lovaza may be confused with LORazepam</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Omacor [multiple international markets] may be confused with Amicar brand name for aminocaproic acid [US]</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) reported a case of a foam plastic cup dissolving after contact with the liquid contents from a Lovaza capsule. ISMP is requesting the manufacturer to add warnings to its labeling and that healthcare providers add Lovaza to their list of medications to not crush.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171361\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%: Gastrointestinal: Diarrhea (7% to 15%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (4% to 6%), abdominal pain (3% to 5%), dysgeusia (4%), eructation (3% to 4%), dyspepsia (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pruritus, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Increased LDL cholesterol</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal distension, constipation, flatulence, gastrointestinal disease, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Prolonged bleeding time</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum ALT, increased serum AST</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Nasopharyngitis, oropharyngeal pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Anaphylaxis, cardiac arrhythmia, hemorrhagic diathesis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171373\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity (eg, anaphylactic reaction) to omega-3 fatty acids or any component of formulation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171359\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fish allergy: Use with caution in patients with known allergy or sensitivity to fish and/or shellfish.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic effects: ALT may increase without concurrent AST increase; periodically monitor hepatic transaminases in patients with hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lipid effects: May increase LDL levels; periodically monitor LDL levels.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Prolongation of bleeding time: Prolongation of bleeding time not exceeding normal limits has been observed in some clinical studies with omega-3 fatty acids; use with caution in patients with coagulopathy or in those receiving therapeutic anticoagulation or antiplatelet therapy. Monitor for changes in INR following initiation and dosage changes of omega-3 fatty acids in patients receiving warfarin.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Atrial fibrillation (AF): Omega-3 fatty acids are not indicated for the treatment of AF or flutter. Recurrent AF or flutter may occur in patients with symptomatic paroxysmal or persistent AF treated with omega-3 fatty acids; more frequent occurrences were observed with omega-3 fatty acids in the first 2 to 3 months of therapy compared to placebo in clinical trials. However, the clinical significance of these results is uncertain.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Conditions associated with abnormal lipids: Manage concurrent conditions (eg, diabetes, hypothyroidism, excessive alcohol intake) that may contribute to lipid abnormalities.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Should be used as an adjunct to diet therapy and exercise and only in those with very high triglyceride levels (&ge;500 mg/dL). Secondary causes of hyperlipidemia should be ruled out prior to therapy. The effect, if any, of omega-3 fatty acids on the risk of pancreatitis or cardiovascular mortality and morbidity in patients with severe hypertriglyceridemia is not known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299789\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171362\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10255&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Omega-3 Fatty Acids may enhance the antiplatelet effect of Agents with Antiplatelet Properties. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticoagulants: Omega-3 Fatty Acids may enhance the anticoagulant effect of Anticoagulants. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibrutinib: Omega-3 Fatty Acids may enhance the antiplatelet effect of Ibrutinib. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171364\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171375\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. Adequate intake of omega-3 fatty acids is recommended during pregnancy (IOM 2005; Nordgren 2017). Maternal use of supplements or dietary consumption of omega-3 fatty acids (containing eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA]) influences fetal concentrations (B&uuml;y&uuml;kuslu 2017; Coletta 2010; Miles 2011).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Triglyceride concentrations increase during pregnancy as required for normal fetal development. When increases are greater than expected, supervised dietary interventions that include omega-3 fatty acids may be initiated. In women who develop very severe hypertriglyceridemia and are at risk for pancreatitis, use of prescription omega-3 fatty acid products may be considered (Avis 2009; Berglund 2012; Jacobson 2015; Wong 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20548542\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Omega-3 fatty acids are present in breast milk and dietary supplementation may influence milk concentrations (IOM 2005). According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171376\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Dietary modification is important in the control of severe hypertriglyceridemia. Maintain standard cholesterol-lowering diet during therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171366\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Triglycerides and other lipids (LDL-C) should be monitored at baseline and periodically. In patients with hepatic impairment, monitor hepatic transaminase levels, particularly ALT, periodically.</p>\n    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">\n      <i>2013 ACC/AHA Blood Cholesterol Guideline recommendations (Stone, 2013):</i> Consider evaluation for GI disturbances, skin changes, and bleeding during therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171358\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Reduction in the hepatic production of triglyceride-rich very low-density lipoproteins (VLDL). Possible cellular mechanisms include inhibition of acyl CoA:1,2 diacylglycerol acyltransferase, increased hepatic mitochondrial and peroxisomal beta-oxidation, and a reduction in the hepatic synthesis of triglycerides.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25177458\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Omega-3-carboxylic acids: Directly absorbed in the small intestine. Administration with a high-fat meal results in an increased overall exposure of total and free baseline-adjusted EPA by ~140% and 80%, respectively, compared to fasting conditions; a 40% increase in AUC occurred for baseline-adjusted free DHA.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Icosapent ethyl: De-esterified to active metabolite (EPA) which is absorbed in the small intestine</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>dss</sub>: EPA: ~88 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: EPA: &gt;99%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: EPA and DHA are mainly oxidized in the liver similar to fatty acids derived from dietary sources. EPA: minor via CYP-450</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: EPA: ~37 to 89 hours; DHA: ~46 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Omega-3-carboxylic acids: Following repeat dosing with low-fat meals for ~2 weeks (steady state): EPA: 5 to 8 hours; DHA: 5 to 9 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Icosapent ethyl: EPA: ~5 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3422228\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule, delayed release</b> (Pro Nutrients Omega 3 Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">332.5 mg (50): $9.90</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Dialyvite Omega-3 Concentrate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mg (60): $9.86</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Lovaza Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (120): $348.76</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Ocean Blue MiniCaps Omega-3 Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">350 mg (60): $21.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Omega Power Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1050 mg (30): $16.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Omega-3 2100 Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1050 mg (30): $7.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Omega-3-acid Ethyl Esters Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (120): $248.13</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Sea-Omega Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mg (50): $7.07</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Vascepa Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 g (240): $391.13</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (120): $334.30</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Chewable</b> (Omega-3 IQ Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">240 mg (90): $22.89</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5539860\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Agemo (PK);</li>\n      <li>Dualtis (GB);</li>\n      <li>Epax (EC);</li>\n      <li>Equiplen (PE);</li>\n      <li>Nebbaro (GB);</li>\n      <li>Omacor (AE, AR, AT, AU, BE, BG, BH, CR, CY, CZ, DE, DO, EE, ES, FI, FR, GB, GR, GT, HN, HR, HU, IE, IL, KR, KW, LK, LT, LU, LV, MT, MY, NI, NL, NO, PA, PL, PT, QA, RO, RU, SA, SI, SK, SV, TH);</li>\n      <li>Omakor (UA);</li>\n      <li>Omaron (KR);</li>\n      <li>Triomar (IL);</li>\n      <li>Ysomega (FR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19741526\"></a>Avis HJ, Hutten BA, Twickler MT, et al. Pregnancy in women suffering from familial hypercholesterolemia: a harmful period for both mother and newborn? <i>Curr Opin Lipidol</i>. 2009;20(6):484-490. doi: 10.1097/MOL.0b013e3283319127.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omega-3-acid-ethyl-esters-fish-oil-drug-information/abstract-text/19741526/pubmed\" target=\"_blank\" id=\"19741526\">19741526</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bays HE, Ballantyne CM, Kastelein JJ, Isaacsohn JL, Braeckman RA, Soni PN. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, Placebo-controlled, Randomized, Double-blind, 12-week study with an open-label Extension [Marine] trial. <i>Am J Cardiol</i>. 2011;108(5):682-690.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omega-3-acid-ethyl-esters-fish-oil-drug-information/abstract-text/21683321/pubmed\" target=\"_blank\" id=\"21683321\">21683321</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berglund L, Brunzell JD, Goldberg AC, et al, &quot;Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline,&quot; <i>J Clin Endocrinol Metab</i>, 2012, 97(9):2969-89.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omega-3-acid-ethyl-esters-fish-oil-drug-information/abstract-text/22962670/pubmed\" target=\"_blank\" id=\"22962670\">22962670</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"28987719\"></a>B&uuml;y&uuml;kuslu N, Oval&#305; S, Altunta&#351; &#350;L, Bat&#305;rel S, Yi&#287;it P, Garipa&#287;ao&#287;lu M. Supplementation of docosahexaenoic acid (DHA) / Eicosapentaenoic acid (EPA) in a ratio of 1/1.3 during the last trimester of pregnancy results in EPA accumulation in cord blood. <i>Prostaglandins Leukot Essent Fatty Acids</i>. 2017;125:32-36. doi: 10.1016/j.plefa.2017.08.005.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omega-3-acid-ethyl-esters-fish-oil-drug-information/abstract-text/28987719/pubmed\" target=\"_blank\" id=\"28987719\">28987719</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Coletta JM, Bell SJ, Roman AS. Omega-3 Fatty acids and pregnancy. <i>Rev Obstet Gynecol</i>. 2010;3(4):163-171.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omega-3-acid-ethyl-esters-fish-oil-drug-information/abstract-text/21364848/pubmed\" target=\"_blank\" id=\"21364848\">21364848</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Donadio JV and Grande JP, &ldquo;The Role of Fish Oil/Omega-3 Fatty Acids in the Treatment of IgA Nephropathy,&rdquo; <i>Semin Nephrol</i>, 2004, 24(3):225-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omega-3-acid-ethyl-esters-fish-oil-drug-information/abstract-text/15156528/pubmed\" target=\"_blank\" id=\"15156528\">15156528</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11274240\"></a>Donadio JV Jr, Larson TS, Bergstralh EJ, et al, &ldquo;A Randomized Trial of High-Dose Compared With Low-Dose Omega-3 Fatty Acids in Severe IgA Nephropathy,&rdquo; <i>J Am Soc Nephrol</i>, 2001, 12(4):791-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omega-3-acid-ethyl-esters-fish-oil-drug-information/abstract-text/11274240/pubmed\" target=\"_blank\" id=\"11274240\">11274240</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Durrington PN, Bhatnagar D, Mackness MI, et al, &ldquo;An Omega-3 Polyunsaturated Fatty Acid Concentrate Administered for One Year Decreased Triglycerides in Simvastatin Treated Patients With Coronary Heart Disease and Persisting Hypertriglyceridaemia,&rdquo; <i>Heart</i>, 2001, 85(5):544-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omega-3-acid-ethyl-esters-fish-oil-drug-information/abstract-text/11303007/pubmed\" target=\"_blank\" id=\"11303007\">11303007</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Epanova (omega-3-carboxylic acids) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals; March 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goldberg AS, Hegele RA. Severe hypertriglyceridemia in pregnancy. <i>J Clin Endocrinol Metab</i>. 2012;97(8):2589-2596.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omega-3-acid-ethyl-esters-fish-oil-drug-information/abstract-text/22639290/pubmed\" target=\"_blank\" id=\"22639290\">22639290</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16684077\"></a>Harris D, Thomas M, Johnson D, Nicholls K, Gillin A; Caring for Australasians with Renal Impairment (CARI). The CARI guidelines. Prevention of progression of kidney disease. <i>Nephrology (Carlton)</i>. 2006;11(suppl 1):S2-S197.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omega-3-acid-ethyl-esters-fish-oil-drug-information/abstract-text/16684077/pubmed\" target=\"_blank\" id=\"16684077\">16684077</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Harris WS, Ginsberg HN, Arunakul N, et al, &ldquo;Safety and Efficacy of Omacor in Severe Hypertriglyceridemia,&rdquo; <i>J Cardiovasc Risk</i>, 1997, 4(5-6):385-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omega-3-acid-ethyl-esters-fish-oil-drug-information/abstract-text/9865671/pubmed\" target=\"_blank\" id=\"9865671\">9865671</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    IOM (Institute of Medicine). <i>Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids</i>. Washington, DC: The National Academies Press. 2005.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26699442\"></a>Jacobson TA, Maki KC, Orringer CE, et al; NLA Expert Panel. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 2 [published correction appears in: J Clin Lipidol. 2016;10(1):211.]. <i>J Clin Lipidol</i>. 2015;9(6)(suppl):S1-S122.e1. doi: 10.1016/j.jacl.2015.09.002.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omega-3-acid-ethyl-esters-fish-oil-drug-information/abstract-text/26699442/pubmed\" target=\"_blank\" id=\"26699442\">26699442</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kotwal S, Jun M, Sullivan D, et al, &quot;Omega 3 Fatty Acids and Cardiovascular Outcomes: Systematic Review and Meta-Analysis,&quot; <i>Circ Cardiovasc Qual Outcomes</i>, 2012, 5(6):808-18.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omega-3-acid-ethyl-esters-fish-oil-drug-information/abstract-text/23110790/pubmed\" target=\"_blank\" id=\"23110790\">23110790</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kowey PR, Reiffel JA, Ellenbogen KA, et al, &ldquo;Efficacy and Safety of Prescription Omega-3 Fatty Acids for the Prevention of Recurrent Symptomatic Atrial Fibrillation: A Randomized Controlled Trial,&rdquo; <i>JAMA</i>, 2010, 304(21):2363-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omega-3-acid-ethyl-esters-fish-oil-drug-information/abstract-text/21078810/pubmed\" target=\"_blank\" id=\"21078810\">21078810</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kris-Etherton PM, Harris WS, Appel LJ; American Heart Association (AHA). Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. <i>Circulation</i>. 2002;106(21):2747-2757. Erratum in <i>Circulation</i>. 2003;107(3):512.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omega-3-acid-ethyl-esters-fish-oil-drug-information/abstract-text/12438303/pubmed\" target=\"_blank\" id=\"12438303\">12438303</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15161954\"></a>Laville M, Alamartine E. Treatment options for IgA nephropathy in adults: a proposal for evidence-based strategy.<i> Nephrol Dial Transplant</i>. 2004;19(8):1947-1951.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omega-3-acid-ethyl-esters-fish-oil-drug-information/abstract-text/15161954/pubmed\" target=\"_blank\" id=\"15161954\">15161954</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22257542\"></a>Liu L, Wang L. Omega-3 fatty acids therapy for IgA nephropathy: a meta-analysis of randomized controlled trials. <i>Clin Nephrol</i>. 2012;77(2):119-125.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omega-3-acid-ethyl-esters-fish-oil-drug-information/abstract-text/22257542/pubmed\" target=\"_blank\" id=\"22257542\">22257542</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"Lovaza.2015.09\"></a>Lovaza (omega-3-acid ethyl esters) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; September 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Macchia A, Grancelli H, Varini S, et al, &ldquo;Omega-3 Fatty Acids for the Prevention of Recurrent Symptomatic Atrial Fibrillation,&rdquo; <i>J Am Coll Cardiol</i>, 2013, 61(4):463&ndash;8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omega-3-acid-ethyl-esters-fish-oil-drug-information/abstract-text/23265344/pubmed\" target=\"_blank\" id=\"23265344\">23265344</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Miles EA, Noakes PS, Kremmyda LS, et al. The Salmon in Pregnancy Study: study design, subject characteristics, maternal fish and marine n-3 fatty acid intake, and marine n-3 fatty acid status in maternal and umbilical cord blood. <i>Am J Clin Nutr</i>. 2011;94(6 suppl):1986S-1992S.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omega-3-acid-ethyl-esters-fish-oil-drug-information/abstract-text/21849598/pubmed\" target=\"_blank\" id=\"21849598\">21849598</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. <i>Circulation</i>. 2011;123(20):2292-2333.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omega-3-acid-ethyl-esters-fish-oil-drug-information/abstract-text/21502576/pubmed\" target=\"_blank\" id=\"21502576\">21502576</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mozaffarian D, Marchioli R, Macchia A, et al, &quot;Fish Oil and Postoperative Atrial Fibrillation: The Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) Randomized Trial,&quot; <i>JAMA</i>, 2012, 308(19):2001-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omega-3-acid-ethyl-esters-fish-oil-drug-information/abstract-text/23128104/pubmed\" target=\"_blank\" id=\"23128104\">23128104</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nodari S, Triggiani M, Campia U, et al, &ldquo;n-3 Polyunsaturated Fatty Acids in the Prevention of Atrial Fibrillation Recurrences after Electrical Cardioversion: A Prospective, Randomized Study,&rdquo; <i>Circulation</i>, 2011, 124(10):1100-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omega-3-acid-ethyl-esters-fish-oil-drug-information/abstract-text/21844082/pubmed\" target=\"_blank\" id=\"21844082\">21844082</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"28245632\"></a>Nordgren TM, Lyden E, Anderson-Berry A, Hanson C. Omega-3 fatty acid intake of pregnant women and women of childbearing age in the United States: potential for deficiency? <i>Nutrients</i>. 2017;9(3).pii:E197. doi: 10.3390/nu9030197.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omega-3-acid-ethyl-esters-fish-oil-drug-information/abstract-text/28245632/pubmed\" target=\"_blank\" id=\"28245632\">28245632</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Papadakis EP, Sarigianni M, Mikhailidis DP, Mamopoulos A, Karagiannis V. Acute pancreatitis in pregnancy: an overview. <i>Eur J Obstet Gynecol Reprod Biol</i>. 2011;159(2):261-266.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omega-3-acid-ethyl-esters-fish-oil-drug-information/abstract-text/21840110/pubmed\" target=\"_blank\" id=\"21840110\">21840110</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rizos EC, Ntzani EE, Bika E, et al, &quot;Association Between Omega-3 Fatty Acid Supplementation and Risk of Major Cardiovascular Disease Events: A Systematic Review and Meta-analysis,&quot; <i>JAMA</i>, 2012, 308(10):1024-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omega-3-acid-ethyl-esters-fish-oil-drug-information/abstract-text/22968891/pubmed\" target=\"_blank\" id=\"22968891\">22968891</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Siscovick DS, Barringer TA, Fretts AM, Wu JH, Lichtenstein AH, Costello RB, Kris-Etherton PM; American Heart Association Nutrition Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Epidemiology and Prevention; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology. Omega-3 polyunsaturated fatty acid (fish oil) supplementation and the prevention of clinical cardiovascular disease: a science advisory from the American Heart Association. <i>Circulation</i>. 2017;135(15):e867-e884. doi: 10.1161/CIR.0000000000000482.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omega-3-acid-ethyl-esters-fish-oil-drug-information/abstract-text/28289069/pubmed\" target=\"_blank\" id=\"28289069\">28289069</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stalenhoef AF, de Graaf J, Wittekoek ME, et al, &ldquo;The Effect of Concentrated n-3 Fatty Acids Versus Gemfibrozil on Plasma Lipoproteins, Low Density Lipoprotein Heterogeneity and Oxidizability in Patients With Hypertriglyceridemia,&rdquo; <i>Atherosclerosis</i>, 2000, 153(1):129-38.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omega-3-acid-ethyl-esters-fish-oil-drug-information/abstract-text/11058707/pubmed\" target=\"_blank\" id=\"11058707\">11058707</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stone NJ, Robinson J, Lichtenstein AH, et al, 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published online ahead of print November 12, 2013]. <i>Circulation</i>. 2013; doi: 10.1161/01.cir.0000437738.63853.7a.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omega-3-acid-ethyl-esters-fish-oil-drug-information/abstract-text/24222016/pubmed\" target=\"_blank\" id=\"24222016\">24222016</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vascepa (icosapent ethyl) [prescribing information]. Bedminster, NJ: Amarin Pharma Inc; February 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27512474\"></a>Wong B, Ooi TC, Keely E. Severe gestational hypertriglyceridemia: A practical approach for clinicians. <i>Obstet Med</i>. 2015;8(4):158-167. doi: 10.1177/1753495X15594082.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omega-3-acid-ethyl-esters-fish-oil-drug-information/abstract-text/27512474/pubmed\" target=\"_blank\" id=\"27512474\">27512474</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10255 Version 174.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F171381\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F171400\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F171384\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F171385\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F171386\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15795613\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F171368\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F24526958\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F25177479\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F24757877\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F171371\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F171370\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25469482\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F1959598\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F171361\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F171373\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F171359\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299789\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F171362\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F171364\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F171375\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20548542\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F171376\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F171366\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F171358\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F25177458\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F3422228\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F5539860\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10255|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=omega-3-acid-ethyl-esters-fish-oil-patient-drug-information\" class=\"drug drug_patient\">Omega-3-acid ethyl esters (fish oil): Patient drug information</a></li></ul></div></div>","javascript":null}